癌症中磷脂酰肌醇-3-激酶（PI3K）/AKT/雷帕霉素哺乳动物靶标激活的异质性：PI3K亚型特异性重要吗？ - Suppr

Suppr

超能文献

Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?

作者信息

Cintas Célia, Guillermet-Guibert Julie

机构信息

INSERM U1037, CRCT, Université Toulouse III Paul Sabatier, Toulouse, France.

Laboratoire d'Excellence TouCAN, Toulouse, France.

出版信息

Front Oncol. 2018 Jan 22;7:330. doi: 10.3389/fonc.2017.00330. eCollection 2017.

DOI:10.3389/fonc.2017.00330

PMID:29404273

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5786822/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a38/5786822/0336c789bfec/fonc-07-00330-g001.jpg

相似文献

Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?癌症中磷脂酰肌醇-3-激酶（PI3K）/AKT/雷帕霉素哺乳动物靶标激活的异质性：PI3K亚型特异性重要吗？

Front Oncol. 2018 Jan 22;7:330. doi: 10.3389/fonc.2017.00330. eCollection 2017.

Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.针对磷脂酰肌醇 3-激酶 (PI3K)/AKT/哺乳动物雷帕霉素靶蛋白 (mTOR) 通路：治疗鳞状细胞肺癌的新兴策略。

Cancer Treat Rev. 2014 Sep;40(8):980-9. doi: 10.1016/j.ctrv.2014.06.006. Epub 2014 Jul 3.

Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.抑制磷脂酰肌醇3-激酶/蛋白激酶B/雷帕霉素哺乳动物靶标信号通路而非丝裂原活化蛋白激酶/细胞外信号调节激酶信号通路，可减弱层粘连蛋白介导的小细胞肺癌细胞存活以及对甲磺酸伊马替尼或化疗的耐药性。

Cancer Res. 2005 Sep 15;65(18):8423-32. doi: 10.1158/0008-5472.CAN-05-0058.

Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.高血糖症与I期试验中的磷脂酰肌醇3激酶/蛋白激酶B/雷帕霉素哺乳动物靶点（PI3K/AKT/mTOR）抑制剂：发生率、预测因素及管理

Oncologist. 2016 Jul;21(7):855-60. doi: 10.1634/theoncologist.2015-0248. Epub 2016 May 5.

WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.WJD008 是一种双重磷脂酰肌醇 3-激酶 (PI3K)/雷帕霉素哺乳动物靶蛋白 (mTOR) 抑制剂，可阻断 PI3K 信号通路，并抑制具有致癌性 PI3K 突变的转化细胞的增殖。

J Pharmacol Exp Ther. 2010 Sep 1;334(3):830-8. doi: 10.1124/jpet.110.167940. Epub 2010 Jun 3.

Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.PI3K/AKT/mTOR 通路在弥漫大 B 细胞淋巴瘤中的激活：利妥昔单抗的临床意义和抑制作用。

Ann Hematol. 2013 Oct;92(10):1351-8. doi: 10.1007/s00277-013-1770-9. Epub 2013 May 2.

Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin is necessary for hypoxia-induced pulmonary artery adventitial fibroblast proliferation.磷脂酰肌醇3激酶、Akt和雷帕霉素哺乳动物靶蛋白的激活对于缺氧诱导的肺动脉外膜成纤维细胞增殖是必需的。

J Appl Physiol (1985). 2005 Feb;98(2):722-31. doi: 10.1152/japplphysiol.00715.2004. Epub 2004 Oct 22.

Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts.甲状腺激素通过磷脂酰肌醇3激酶在人成纤维细胞中诱导Akt/蛋白激酶B-雷帕霉素哺乳动物靶标-p70S6K级联反应的快速激活。

Mol Endocrinol. 2005 Jan;19(1):102-12. doi: 10.1210/me.2004-0093. Epub 2004 Sep 23.

Involvement of phosphatidylinositol-3 kinase/Akt/mammalian target of rapamycin/peroxisome proliferator-activated receptor γ pathway for induction and maintenance of neuropathic pain.磷脂酰肌醇-3 激酶/蛋白激酶 B/哺乳动物雷帕霉素靶蛋白/过氧化物酶体增殖物激活受体 γ 通路在神经病理性疼痛的诱导和维持中的作用。

Biochem Biophys Res Commun. 2018 May 5;499(2):253-259. doi: 10.1016/j.bbrc.2018.03.139. Epub 2018 Mar 22.

Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.雷帕霉素哺乳动物靶点在转化的B淋巴细胞中的激活是营养依赖性的，但不依赖于Akt、丝裂原活化蛋白激酶/细胞外信号调节激酶激酶、胰岛素生长因子-I和血清。

Cancer Res. 2005 Sep 1;65(17):7800-8. doi: 10.1158/0008-5472.CAN-04-4180.

引用本文的文献

A Meta-analysis of the Risk of Adverse Cardiovascular Events in Patients with Cancer Treated with Inhibitors of the PI3K/AKT/mTOR Signaling Pathway.PI3K/AKT/mTOR信号通路抑制剂治疗癌症患者不良心血管事件风险的Meta分析

Cardiovasc Toxicol. 2025 Feb;25(2):269-281. doi: 10.1007/s12012-024-09933-7. Epub 2024 Nov 9.

Synthesis of Novel 2,9-Disubstituted-6-morpholino Purine Derivatives Assisted by Virtual Screening and Modelling of Class I PI3K Isoforms.通过虚拟筛选和I类PI3K亚型建模辅助合成新型2,9-二取代-6-吗啉代嘌呤衍生物

Polymers (Basel). 2023 Mar 29;15(7):1703. doi: 10.3390/polym15071703.

Update on the role of copanlisib in hematologic malignancies.库潘尼西在血液系统恶性肿瘤中作用的最新进展。

Ther Adv Hematol. 2021 Apr 9;12:20406207211006027. doi: 10.1177/20406207211006027. eCollection 2021.

Pre-existing Cell States Control Heterogeneity of Both EGFR and CXCR4 Signaling.预先存在的细胞状态控制EGFR和CXCR4信号传导的异质性。

Cell Mol Bioeng. 2020 Jul 27;14(1):49-64. doi: 10.1007/s12195-020-00640-1. eCollection 2021 Feb.

Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials.靶向口腔癌中的 AKT/mTOR：机制与临床试验进展。

Int J Mol Sci. 2020 May 6;21(9):3285. doi: 10.3390/ijms21093285.

Short-term cellular memory tunes the signaling responses of the chemokine receptor CXCR4.短期细胞记忆调节趋化因子受体 CXCR4 的信号转导反应。

Sci Signal. 2019 Jul 9;12(589):eaaw4204. doi: 10.1126/scisignal.aaw4204.

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).一项新辅助来曲唑联合阿培利司治疗激素受体阳性、人表皮生长因子受体 2 阴性乳腺癌的 II 期随机研究（NEO-ORB）。

Clin Cancer Res. 2019 May 15;25(10):2975-2987. doi: 10.1158/1078-0432.CCR-18-3160. Epub 2019 Feb 5.

Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.氟维司群为基础的联合治疗方案用于激素受体阳性晚期乳腺癌的二线治疗。

Target Oncol. 2019 Feb;14(1):1-12. doi: 10.1007/s11523-018-0587-9.

Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics.胰腺癌中的信号靶向治疗与耐药机制：蛋白质组学引领未来发展

Cancers (Basel). 2018 Jun 1;10(6):174. doi: 10.3390/cancers10060174.

本文引用的文献

Targeting PI3K Signaling in Combination Cancer Therapy.联合癌症治疗中靶向PI3K信号通路

Trends Cancer. 2017 Jun;3(6):454-469. doi: 10.1016/j.trecan.2017.04.002. Epub 2017 May 14.

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.一项在晚期实体瘤患者中进行的 GSK2636771（一种磷酸肌醇 3 激酶β选择性抑制剂）首次人体研究。

Clin Cancer Res. 2017 Oct 1;23(19):5981-5992. doi: 10.1158/1078-0432.CCR-17-0725. Epub 2017 Jun 23.

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.PI3K/AKT/mTOR信号通路改变的泛癌蛋白质基因组图谱

Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.一项在晚期实体恶性肿瘤患者中进行的、首次人体、I 期、剂量递增研究，评估 TAK-117，一种选择性 PI3Kα 亚型抑制剂的安全性、耐受性、药代动力学和初步疗效。

Clin Cancer Res. 2017 Sep 1;23(17):5015-5023. doi: 10.1158/1078-0432.CCR-16-2888. Epub 2017 May 10.

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.基于肿瘤分子谱的分子靶向治疗与晚期癌症的常规治疗（SHIVA）：一项多中心、开放标签、概念验证、随机、对照的 2 期临床试验。

Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.

Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer.测量 PIP3 水平揭示了 p110β 在腔面乳腺癌中对 p110α 特异性抑制剂的早期适应性反应中的意外作用。

Cancer Cell. 2015 Jan 12;27(1):97-108. doi: 10.1016/j.ccell.2014.11.007. Epub 2014 Dec 24.

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.PTEN 突变型肿瘤中 PI3Kα 信号的反馈抑制可被选择性抑制 PI3Kβ 缓解。

Cancer Cell. 2015 Jan 12;27(1):109-22. doi: 10.1016/j.ccell.2014.11.008. Epub 2014 Dec 24.

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.癌症中的PI3K：异构体的不同作用、激活模式及治疗靶点

Nat Rev Cancer. 2015 Jan;15(1):7-24. doi: 10.1038/nrc3860.

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.一项评估口服泛 PI3K 抑制剂 BKM120（Buparlisib）联合口服 MEK1/2 抑制剂 Trametinib（GSK1120212）在多种晚期实体瘤患者中的 Ib 期剂量递增研究。

Clin Cancer Res. 2015 Feb 15;21(4):730-8. doi: 10.1158/1078-0432.CCR-14-1814. Epub 2014 Dec 10.

Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α.致癌性Kras诱导的胰腺细胞可塑性和癌症起始完全依赖于野生型PI 3激酶p110α。

Genes Dev. 2014 Dec 1;28(23):2621-35. doi: 10.1101/gad.249409.114.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验